Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts

Science Translational Medicine

Volumn 4, Issue 128, 2012, Pages

  Politis, Marios ^a   Wu, Kit ^a   Loane, Clare ^a   Quinn, Niall P ^b   Brooks, David J ^a   Oertel, Wolfgang H ^c   Björklund, Anders ^d   Lindvall, Olle ^d,e   Piccini, Paola ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d LUND UNIVERSITY   (Sweden)

^e LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; FLUORODEOXYGLUCOSE F 18; LEVODOPA; NORADRENALIN; RACLOPRIDE; SEROTONIN;

ADULT; AROUSAL; ARTICLE; BASAL GANGLION; BECK DEPRESSION INVENTORY; BRAIN REGION; CELL THERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC NERVE CELL; EMOTION; FATIGUE; FEMALE; HUMAN; IMAGE ANALYSIS; LOCUS CERULEUS; MALE; MESENCEPHALON; MINI MENTAL STATE EXAMINATION; MOOD; MOTOR PERFORMANCE; NERVE CELL NETWORK; NEUROTRANSMISSION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAPHE NUCLEUS; SATIETY; SLEEP DISORDER; STEM CELL; SYMPTOMATOLOGY; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL HALLUCINATION; AGED; CYTOLOGY; METABOLISM; MIDDLE AGED; NERVE CELL; NERVE DEGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; SEROTONINERGIC NERVE CELL; TRANSPLANTATION;

AGED; DOPAMINE; DOPAMINERGIC NEURONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE DEGENERATION; NEURONS; PARKINSON DISEASE; SEROTONERGIC NEURONS;

EID: 84859496019     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003391     Document Type: Article

References (61)

1. K. R. Chaudhuri, D. G. Healy, A. H. Schapira; National Institute for Clinical Excellence, Nonmotor symptoms of Parkinson's disease: Diagnosis and management. Lancet Neurol. 5, 235-245 (2006).
2. M. Politis, K. Wu, S. Molloy, P. G. Bain, K. R. Chaudhuri, P. Piccini, Parkinson's disease symptoms: The patient's perspective. Mov. Disord. 25, 1646-1651 (2010).
3. P. Martinez-Martin, C. Rodriguez-Blazquez, M. M. Kurtis, K. R. Chaudhuri; NMSS Validation Group, The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov. Disord. 26, 399-406 (2011).
4. L. D. Wood, J. J. Neumiller, S. M. Setter, E. K. Dobbins, Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. Am. J. Geriatr. Pharmacother. 8, 294-315 (2010).
5. O. Lindvall, A. Björklund, Cell therapy in Parkinson's disease. NeuroRx 1, 382-393 (2004).
6. M. Politis, K. Wu, C. Loane, N. P. Quinn, D. J. Brooks, S. Rehncrona, A. Bjorklund, O. Lindvall, P. Piccini, Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci. Transl. Med. 2, 38ra46 (2010).
7. M. Politis, Dyskinesias after neural transplantation in Parkinson's disease: What do we know and what is next? BMC Med. 8, 80 (2010).
8. M. Politis, W. H. Oertel, K. Wu, N. P. Quinn, O. Pogarell, D. J. Brooks, A. Bjorklund, O. Lindvall, P. Piccini, Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov. Disord. 26, 1997-2003 (2011).
9. H. Braak, K. Del Tredici, U. Rüb, R. A. de Vos, E. N. Jansen Steur, E. Braak, Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211 (2003).
10. S. J. Kish, Biochemistry of Parkinson's disease: Is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? Adv. Neurol. 91, 39-49 (2003).
11. T. N. Taylor, W. M. Caudle, K. R. Shepherd, A. Noorian, C. R. Jackson, P.M. Iuvone, D. Weinshenker, J. G. Greene, G. W. Miller, Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 29, 8103-8113 (2009).
12. C. Delaville, P. D. Deurwaerdère, A. Benazzouz, Noradrenaline and Parkinson's disease. Front. Syst. Neurosci. 5, 31 (2011).
13. D. M. Kuhn, C. E. Sykes, T. J. Geddes, K. L. Jaunarajs, C. Bishop, Tryptophan hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: Possible link to serotonin deficits and non-motor symptoms in Parkinson's disease. J. Neurochem. 116, 426-437 (2011).
14. I. Boileau, J. J. Warsh, M. Guttman, J. A. Saint-Cyr, T. McCluskey, P. Rusjan, S. Houle, A. A. Wilson, J. H. Meyer, S. J. Kish, Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C]DASB. Mov. Disord. 23, 1776-1780 (2008).
15. B. Ballanger, A. P. Strafella, T. van Eimeren, M. Zurowski, P. M. Rusjan, S. Houle, S. H. Fox, Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch. Neurol. 67, 416-421 (2010).
16. N. Pavese, V. Metta, S. K. Bose, K. R. Chaudhuri, D. J. Brooks, Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 133, 3434-3443 (2010).
17. M. Politis, K. Wu, C. Loane, F. E. Turkheimer, S. Molloy, D. J. Brooks, P. Piccini, Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 75, 1920-1927 (2010).
18. M. Politis, C. Loane, K. Wu, D. J. Brooks, P. Piccini, Serotonergic mediated body mass index changes in Parkinson's disease. Neurobiol. Dis. 43, 609-615 (2011).
19. P. Hagell, A. Schrag, P. Piccini, M. Jahanshahi, R. Brown, S. Rehncrona, H. Widner, P. Brundin, J. C. Rothwell, P. Odin, G. K. Wenning, P. Morrish, B. Gustavii, A. Björklund, D. J. Brooks, C. D. Marsden, N. P. Quinn, O. Lindvall, Sequential bilateral transplantation in Parkinson's disease: Effects of the second graft. Brain 122, 1121-1132 (1999).
20. P. Brundin, O. Pogarell, P. Hagell, P. Piccini, H. Widner, A. Schrag, A. Kupsch, L. Crabb, P. Odin, B. Gustavii, A. Björklund, D. J. Brooks, C. D. Marsden, W. H. Oertel, N. P. Quinn, S. Rehncrona, O. Lindvall, Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123, 1380-1390 (2000).
21. A. F. Leentjens, F. R. Verhey, G. J. Luijckx, J. Troost, The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov. Disord. 15, 1221-1224 (2000).
22. C. D. Silberman, J. Laks, C. F. Capitão, C. S. Rodrigues, I. Moreira, E. Engelhardt, Recognizing depression in patients with Parkinson's disease: Accuracy and specificity of two depression rating scale. Arq. Neuropsiquiatr. 64, 407-411 (2006).
23. P. Piccini, D. J. Brooks, A. Björklund, R. N. Gunn, P. M. Grasby, O. Rimoldi, P. Brundin, P. Hagell, S. Rehncrona, H. Widner, O. Lindvall, Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat. Neurosci. 2, 1137-1140 (1999).
24. P. Piccini, N. Pavese, P. Hagell, J. Reimer, A. Björklund, W. H. Oertel, N. P. Quinn, D. J. Brooks, O. Lindvall, Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 128, 2977-2986 (2005).
25. R. Y. Moore, J. P. Card, in Handbook of Chemical Neuroanatomy: Classical Transmitters in the CNS, Part I, A. Bjorklund, T. Hokfelt, Eds. (Elsevier, Amsterdam, 1984), vol. 2, pp. 123-156.
26. A. Björklund, O. Lindvall, in Handbook of Physiology - The Nervous System: Intrinsic Regulatory Systems of the Brain, Catecholaminergic Brain Stem Regulatory Systems, F. E. Bloom, Ed. (American Physiological Society, Bethesda, MD, 1986), vol. 4, pp. 155-235.
27. R. Y. Moore, A. L. Whone, S. McGowan, D. J. Brooks, Monoamine neuron innervation of the normal human brain: An 18F-DOPA PET study. Brain Res. 982, 137-145 (2003).
28. H. W. Steinbusch, Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience 6, 557-618 (1981).
29. V. Chan-Palay, E. Asan, Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J. Comp. Neurol. 287, 373-392 (1989).
30. M. Gesi, P. Soldani, F. S. Giorgi, A. Santinami, I. Bonaccorsi, F. Fornai, The role of the locus coeruleus in the development of Parkinson's disease. Neurosci. Biobehav. Rev. 24, 655-668 (2000).
31. H. Braak, K. Del Tredici, H. Bratzke, J. Hamm-Clement, D. Sandmann-Keil, U. Rüb, Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J. Neurol. 249 (Suppl. 3), 1-5 (2002).
32. H. Braak, E. Ghebremedhin, U. Rüb, H. Bratzke, K. Del Tredici, Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318, 121-134 (2004).
33. P. Jenner, M. Sheehy, C. D. Marsden, Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: Implications for the treatment of Parkinson's disease. Br. J. Clin. Pharmacol. 15 (Suppl. 2), 277S-289S (1983).
34. P. Gaspar, C. Duyckaerts, C. Alvarez, F. Javoy-Agid, B. Berger, Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease. Ann. Neurol. 30, 365-374 (1991).
35. D. van der Kooy, T. Hattori, Dorsal raphe cells with collateral projections to the caudate-putamen and substantia nigra: A fluorescent retrograde double labeling study in the rat. Brain Res. 186, 1-7 (1980).
36. B. Lavoie, A. Parent, Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J. Comp. Neurol. 299, 1-16 (1990).
37. R. J. D'Amato, R. M. Zweig, P. J. Whitehouse, G. L. Wenk, H. S. Singer, R. Mayeux, D. L. Price, S. H. Snyder, Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann. Neurol. 22, 229-236 (1987).
38. G. M. Halliday, Y. W. Li, P. C. Blumbergs, T. H. Joh, R. G. Cotton, P. R. Howe, W. W. Blessing, L. B. Geffen, Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann. Neurol. 27, 373-385 (1990).
39. W. Paulus, K. Jellinger, The neuropathologic basis of different clinical subgroups of Parkinson's disease. J. Neuropathol. Exp. Neurol. 50, 743-755 (1991).
40. H. Braak, K. Del Tredici, Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology 70, 1916-1925 (2008).
41. M. Politis, K. Wu, C. Loane, L. Kiferle, S. Molloy, D. J. Brooks, P. Piccini, Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol. Dis. 40, 216-221 (2010).
42. S. H. Fox, R. Chuang, J. M. Brotchie, Serotonin and Parkinson's disease: On movement, mood, and madness. Mov. Disord. 24, 1255-1266 (2009).
43. A. J. Hughes, S. E. Daniel, L. Kilford, A. J. Lees, Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181-184 (1992).
44. O. Lindvall, S. Rehncrona, P. Brundin, B. Gustavii, B. Astedt, H. Widner, T. Lindholm, A. Björklund, K. L. Leenders, J. C. Rothwell, R. Frackowiak, C. D. Marsden, B. Johnels, G. Steg, R. Freedman, B. J. Hoffer, Å. Seiger, M. Bygdeman, I. Strömberg, L. Olson, Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch. Neurol. 46, 615-631 (1989).
45. G. K. Wenning, P. Odin, P. Morrish, S. Rehncrona, H. Widner, P. Brundin, J. C. Rothwell, R. Brown, B. Gustavii, P. Hagell, M. Jahanshahi, G. Sawle, A. Björklund, D. J. Brooks, C. D. Marsden, N. P. Quinn, O. Lindvall, Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann. Neurol. 42, 95-107 (1997).
46. S. Rehncrona, A critical review of the current status and possible developments in brain transplantation. Adv. Tech. Stand. Neurosurg. 23, 3-46 (1997).
47. G. Brix, J. Zaers, L. E. Adam, M. E. Bellemann, H. Ostertag, H. Trojan, U. Haberkorn, J. Doll, F. Oberdorfer, W. J. Lorenz, Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J. Nucl. Med. 38, 1614-1623 (1997).
48. 18F]fluoro- L-DOPA kinetics in positron emission tomography. J. Nucl. Med. 33, 1472-1477 (1992).
49. T. J. Spinks, T. Jones, P. M. Bloomfield, D. L. Bailey, M. Miller, D. Hogg, W. F. Jones, K. Vaigneur, J. Reed, J. Young, D. Newport, C. Moyers, M. E. Casey, R. Nutt, Physical characteristics of the ECAT EXACT3D positron tomograph. Phys. Med. Biol. 45, 2601-2618 (2000).
50. 18F-fluoro-L-DOPA PET data from a multicenter study. J. Nucl. Med. 45, 1135-1145 (2004).
51. C. S. Patlak, R. G. Blasberg, J. D. Fenstermacher, Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 3, 1-7 (1983).
52. 18F]dopa-PET study. Brain 122, 1637-1650 (1999).
53. 18F-dopa PET study. Neurobiol. Dis. 29, 381-390 (2008).
54. J. Talairach, P. Tournoux, Co-planar Stereotaxic Atlas of the Human Brain (Thieme, New York, 1988).
55. H. M. Duvernoy, The Human Brain: Surface, Blood Supply, and Three-Dimensional Sectional Anatomy (Springer-Verlag Wien, New York, ed. 2, 1999).
56. R. N. Gunn, A. A. Lammertsma, S. P. Hume, V. J. Cunningham, Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6, 279-287 (1997).
57. S. J. Kish, Y. Furukawa, L. J. Chang, J. Tong, N. Ginovart, A. Wilson, S. Houle, J. H. Meyer, Regional distribution of serotonin transporter protein in postmortem human brain: Is the cerebellum a SERT-free brain region? Nucl. Med. Biol. 32, 123-128 (2005).
58. A. J. Montgomery, K. Thielemans, M. A. Mehta, F. Turkheimer, S. Mustafovic, P. M. Grasby, Correction of head movement on PET studies: Comparison of methods. J. Nucl. Med. 47, 1936-1944 (2006).
59. J. Logan, J. S. Fowler, N. D. Volkow, G. J. Wang, Y. S. Ding, D. L. Alexoff, Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 16, 834-840 (1996).
60. N. Ginovart, A. A. Wilson, J. H. Meyer, D. Hussey, S. Houle, Positron emission tomography quantification of [11C]-DASB binding to the human serotonin transporter: Modeling strategies. J. Cereb. Blood Flow Metab. 21, 1342-1353 (2001).
61. R. B. Innis, V. J. Cunningham, J. Delforge, M. Fujita, A. Gjedde, R. N. Gunn, J. Holden, S. Houle, S. C. Huang, M. Ichise, H. Iida, H. Ito, Y. Kimura, R. A. Koeppe, G. M. Knudsen, J. Knuuti, A. A. Lammertsma, M. Laruelle, J. Logan, R. P. Maguire, M. A. Mintun, E. D. Morris, R. Parsey, J. C. Price, M. Slifstein, V. Sossi, T. Suhara, J. R. Votaw, D. F. Wong, R. E. Carson, Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 27, 1533-1539 (2007).